Director at $MNPR sells 461 shares in insider transaction

Arthur J Klausner, who serves as a director at MNPR, recently made a significant move in the stock market by selling 461 shares of the company on December 18, 2025, for an estimated $31,389. This transaction, disclosed in a recent SEC filing, accounted for roughly 5.0% of their holdings in this particular class of stock. Following this sale, Klausner now retains ownership of 8,762 shares in this category of MNPR stock.

Over the past 6 months, insiders at MNPR have engaged in trading activities on the public market a total of 6 times. Out of these transactions, no purchases were made, and all 6 involved sales. Among the notable movers were Pharma LLC Tactic, who offloaded 550,229 shares for approximately $34,999,956, Christopher M Starr and Chandler Robinson, both divesting 16,800 shares each for an estimated $672,020, and Kim R Tsuchimoto, who sold 8,904 shares for around $356,170. Klausner, on the other hand, made 2 sales, shedding 5,121 shares for an estimated $343,889.

In terms of hedge fund activities related to MNPR, data reveals that 32 institutional investors opted to increase their holdings in the company’s stock, while 27 decided to reduce their positions in the last reported quarter. Wellington Management Group LLP led the way by adding 231,463 shares to their holdings, valued at approximately $18,903,583, followed by Deerfield Management Company, L.P., Saturn V Capital Management LP, TCG Crossover Management, LLC, and Vanguard Group Inc, all making substantial additions to their portfolios.

In the realm of analyst ratings, Wall Street has been closely monitoring MNPR’s performance, with 10 firms issuing buy ratings on the stock. Notably, no sell ratings were provided. Analysts from Chardan Capital, Leerink Partners, Barclays, Oppenheimer, HC Wainwright & Co., Piper Sandler, and BTIG issued positive recommendations, underlining the confidence in MNPR’s future prospects.

On the price target front, multiple analysts have put forth their projections for MNPR, with a median target of $105.50. Notable figures include Chris Raymond from Raymond James, setting a target price of $123.00, Keay Nakae from Chardan Capital with a target of $100.00, and Joseph Schwartz from Leerink Partners aiming for $115.00. These forecasts reflect the optimistic sentiment surrounding MNPR’s potential growth.

In conclusion, the recent insider trading activities, hedge fund movements, analyst ratings, and price targets all point towards a positive outlook for MNPR. It is essential for investors to stay informed about such developments to make well-informed decisions in the stock market.